Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1951 to 1965 of 2170 results for guidelines

  1. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    1 May 2025
    View recommendations

    Sections for TA878

  2. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  3. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

    Technology appraisal guidance
    Published
    26 February 2025
    View recommendations

    Sections for TA1044

  4. Guidance executive

    NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.

  5. Ulcerative colitis: management (CG166)

    This guidance has been updated and replaced by NICE guideline NG130.

    Clinical guideline
    Published
    26 June 2013

  6. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care (CG8)

    This guidance has been updated and replaced by NICE guideline CG186.

    Clinical guideline
    Published
    26 November 2003

  7. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG67)

    This guidance has been updated and replaced by NICE guideline CG181.

    Clinical guideline
    Published
    28 May 2008

  8. Heavy menstrual bleeding: assessment and management (CG44)

    This guidance has been updated and replaced by NICE guideline NG88.

    Clinical guideline
    Last updated
    24 August 2016

  9. Venous thromboembolism: reducing the risk for patients in hospital (CG92)

    This guidance has been updated and replaced by NICE guideline NG89.

    Clinical guideline
    Last updated
    1 June 2015

  10. Improving outcomes in haemato-oncology cancer (CSG3)

    This guidance has been updated and replaced by NICE guideline NG47.

    Cancer service guideline
    Published
    22 October 2003

  11. Smoking: brief interventions and referrals (PH1)

    This guidance has been updated and replaced by NICE guideline NG92.

    Public health guideline
    Published
    29 March 2006

  12. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Evidence summary
    Published
    10 March 2015

  13. Suburethral synthetic sling insertion for stress urinary incontinence in men (IPG256)

    This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional procedures programme.

    Interventional procedures guidance
    Published
    17 March 2008

  14. Insertion of extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in men (IPG224)

    This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.

    Interventional procedures guidance
    Published
    23 July 2007

  15. Executive team

    Day-to-day decision making is the responsibility of NICE's executive team.